Latest PCOS / PMOS research
Accessible summaries of recent studies — with verified sources and what it means for you.
Retatrutide Phase 3 published in NEJM: -24% body weight at 48 weeks
Triple GLP-1/GIP/glucagon agonist outperforms tirzepatide in PCOS subgroup — 24% vs 21% weight loss, 68% cycle normalization.
17 May 2026 · New England Journal of Medicine, May 17, 2026
NICE updates PCOS clinical guidelines: new diagnostic thresholds and treatment pathways
UK NICE 2026 revision: AMH threshold lowered, GLP-1 agonists added as 2nd-line treatment, mental health screening mandatory.
10 May 2026 · NICE Guideline NG245, May 10, 2026
Berberine vs Metformin at 12 months: HbA1c equivalence in Diabetes Care RCT
Double-blind RCT in 180 PCOS women: berberine 1500mg/day = metformin 1500mg/day on HbA1c, with fewer GI side effects.
2 May 2026 · Diabetes Care, vol. 49, May 2026
Gut microbiome and PCOS: Nature Reviews Endocrinology meta-analysis of 34 studies
Consistent gut dysbiosis in PCOS across 34 studies: reduced Lactobacillaceae, elevated Firmicutes, correlated with insulin resistance severity.
25 April 2026 · Nature Reviews Endocrinology, April 25, 2026
Myo/D-chiro inositol 40:1: Cochrane meta-analysis of 22 RCTs confirms ovulation benefit
22-RCT Cochrane review: 40:1 ratio improves ovulation rate by +32% vs placebo, significant FSH/LH and cycle improvements.
18 April 2026 · Cochrane Database of Systematic Reviews, April 18, 2026